Schalm S W
Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Chemioterapia. 1988 Dec;7 Suppl 3:26-9.
The possible enhancement effect of acyclovir or its prodrug descyclovir in combination with human lymphoblastoid interferon (Wellferon) was studied in three trials with a total of 146 patients with chronic hepatitis B; a pilot study (Study 1; n = 12), two randomized controlled studies, one with a combination of descyclovir and interferon (Study 2; n = 36) and the other using acyclovir and interferon (Study 3; n = 98). The results from Study 1 and 2 showed that combination therapy with interferon and acyclovir or descyclovir (n = 25) was associated with a 40% HBe+ seroconversion rate, compared to 30% with interferon treatment alone (n = 10), 18% with acyclovir alone (n = 11) and 0% with no treatment (n = 18). Preliminary results from Study 3 on rate of HBe-seroconversion are similar to previous studies. Antiviral therapy with interferon and acyclovir or its prodrug, have resulted in significantly enhanced HBe seroconversion. The intravenous acyclovir component of combination therapy is however cumbersome and research should be directed towards finding an oral anti-hepatitis drug.
在三项试验中，对总共146例慢性乙型肝炎患者研究了阿昔洛韦或其前体药物去环鸟苷与人类淋巴母细胞干扰素（惠福仁）联合使用可能产生的增强效果；一项试点研究（研究1；n = 12），两项随机对照研究，一项是去环鸟苷与干扰素联合使用（研究2；n = 36），另一项使用阿昔洛韦与干扰素（研究3；n = 98）。研究1和2的结果表明，干扰素与阿昔洛韦或去环鸟苷联合治疗（n = 25）的HBe + 血清学转换率为40%，而单独使用干扰素治疗（n = 10）为30%，单独使用阿昔洛韦（n = 11）为18%，未治疗（n = 18）为0%。研究3关于HBe血清学转换率的初步结果与先前研究相似。干扰素与阿昔洛韦或其前体药物的抗病毒治疗显著提高了HBe血清学转换率。然而，联合治疗中的静脉注射阿昔洛韦成分使用不便，研究应致力于寻找口服抗肝炎药物。
